Company to receive approximately $7 million in funding from the Gates Foundation to use its srRNA platform to develop malaria and HIV candidates to address two of the world’s most persistent public health burdens, subject to humanitarian licensing terms.
Replicate Bioscience press release
San Diego, Calif., January 8, 2026 – Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today announced that it has been awarded two research grants from the Gates Foundation. A grant of approximately $3.5 million will be awarded to support the development of a low-dose, multigenic RNA-based malaria vaccine platform, with the goal of expanding access to effective malaria prevention tools in low- and middle-income countries. A second grant of approximately $3.5 million will support the development of a novel self-replicating RNA-based HIV vaccine candidate to help accelerate progress toward effective and accessible HIV prevention.
Read the full press release here.
Source : Replicate Bioscience
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.